Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women

E(2)/NETA 25/125 Estragest TTS was more effective than placebo in reducing the activation frequency of bone remodeling and in preventing bone loss at the spine and hip. Effects on the hip were similar to those observed for higher doses of estrogen.